Capricor outlines BLA amendment plan as FDA signals willingness to review, with PDUFA date set for August 22 (NASDAQ:CAPR)
· seekingalpha.com
Capricor (CAPR) Q2 2026 earnings call: Deramiocel FDA review, Aug.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...